Indian Vx manufacturers have played an extremely important role in producing affordable childhood vaccines for LMICs. But the COVID crisis in India is a somber reminder that we need a more diversified Vx supply base. My opinion piece in @nytimes👇 🧵(1/2) nytimes.com/2021/05/20/opi…
1) We need to get a better handle on manufacturing capacity- rigorously, systematically, & routinely. 2) We need to expand vaccine manufacturing into new regions. Start by exploring if sustainable manuf hubs could be added in locations such as Rwanda, Senegal, Panama, & more.
@Yadav_supplychn @nytimes Thanks for sharing, Prashant! Insightful piece. Q: what do you see new Vx supply hubs doing in non-surge-demand periods when buyers may not want to pay a "resilience premium"?